Exenatide

Drug / Medication

An older, first-generation GLP-1 (Gen 1) receptor agonist, part of the triple therapy in the EDI Study and Qatar study, described as effective despite its age.

Mentioned in 3 videos

Videos Mentioning Exenatide

Dave Ricks, CEO of Eli Lilly | The All-In Interview

Dave Ricks, CEO of Eli Lilly | The All-In Interview

All-In Podcast

Eli Lilly's first GLP-1 drug, discovered in the saliva of a Gila monster, which helped lower blood sugar and caused weight loss.

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

Andrew Huberman

The first GLP-1 drug approved in 2005 for diabetes, derived from Gila monster venom, with a half-life of about 2 hours.

337- Insulin resistance masterclass: The full body impact of metabolic dysfunction, treatment & more

337- Insulin resistance masterclass: The full body impact of metabolic dysfunction, treatment & more

Peter Attia MD

An older, first-generation GLP-1 (Gen 1) receptor agonist, part of the triple therapy in the EDI Study and Qatar study, described as effective despite its age.